Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency 01 December
Dupixent® Approved as the First Targeted Medicine in the European Union in Over a Decade for Chronic Spontaneous Urticaria 25 November
EYLEA HD® Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion and for Monthly Dosing Across Approved Indications 19 November
